Billions of people use this alternative, but only a small percentage of these herbal medicines have been administered under medical supervision. Many factors contribute to the use of medicinal plants, especially those related to economic and social status. Thus, the research job with medicinal plants aims to produce drugs with lower cost, thus more accessible to the population. In addition, the Brazilian industry of drugs concentrates a significant portion of resources in the production of herbal medicines [8] .
In South American countries, medicinal plants of native flora are consumed with little or no scientific validation of their pharmacological properties, propagated by users and traders. Researches conducted to assess the safe use of medicinal plants and herbal medicines in Brazil are still incipient. Therefore, there is no sales control and marketing by official bodies in the street markets, public markets or health food stores. Multidisciplinary studies involving ethnobotanists, chemists, pharmacologists and agronomists are needed so that the knowledge of medicinal plants can be expanded: how they act, what their toxic and side effects are, how would their interactions with new allopathic drugs be and which would be the most appropriate strategies for quality control and production of herbal medicines [9, 10] .
In this context, it is understood that there is a great need to prospect and develop new drugs to improve the current pharmacological arsenal for the treatment of diseases. In this regard, the triterpene mixture of AMY of P. heptaphyllum becomes attractive for the industry due to its pharmacological activities already described. Therefore, it seemed important to our team to collect information from the current literature on the biological activities of a-and b-amyrin from P. heptaphyllum and to bring them together in this work.
M E T H O D S

Search strategy
The literature review was performed by two independent authors (Nogueira AO and Aragão GF) using the literature data on the effects of a-and b-amyrin already described. Articles published in English with no time limits were searched in relevant Web datasets (PubMed, SciELO, LILACS, SciFinder and Science Direct).
The combinations of search terms, together with MESH terms, employed in this review were as follows: '(alpha OR beta-amyrin) AND Protium heptaphyllum AND (amyrins)'. These included (('alpha-amyrin ' As inclusion criteria, we considered published experimental studies in English and Portuguese, which used the mixture of a-and/or b-amyrin from P. heptaphyllum. We excluded studies that did not use a-and/or bamyrin from P. heptaphyllum and review articles with humans or other animal species. The following items were evaluated in the articles selected: dose used, route of administration, mechanism of action and main results obtained.
For the inclusion of the scientific articles, a flow chart of steps (Figure 2) , as recommended by the PRISMA flow chart was created [11] . Briefly, the identification of records of the use of a-and/or b-amyrin from P. heptaphyllum in the selected databases was performed and this screening step began with the reading of title and abstract of the articles, and then duplicate records were deleted. In the next step, the articles were considered eligible from the methodology used, excluding clinical trials and patent registration, those that did not correspond to experimental studies. Finally, only the records actually present in the chosen databases were included, after the entire content of the article was consulted and the results were analyzed by descriptive statistics.
R E S U L T S A N D D I S C U S S I O N
During the initial search in the databases, 516 documents were identified and divided into original research articles, patent registration, review articles or short communications. After careful reading, the duplicate records were sorted and removed, leaving only 303 documents. Considering the adopted inclusion criteria, 183 studies were found in the databases consulted, of which 31 (16.94%) were found in PUBMED, 37 (20.22%) in SciELO, 22 (12.02%) in LILACS, 54 in SciFinder (29.51%), 39 (21.31%) in Science Direct ( Table I) .
After the complete reading of the articles, only 14 (7.65%) of the 183 found in the databases were considered for this review, considering 169 of the total selected described the alpha or beta amyrin of other plants and not Protium heptaphyllum. This criterion was established because the proportion of these compounds may vary between species, and in P. heptaphyllum this ratio is from 2 (a-amyrin) to 1 (bamyrin).
During the research, it was identified that some biological activities were described with greater incidence in the literature, such as an anti-inflammatory effect present in the results section of five articles (35.71%) and an antinociceptive effect in three articles (21.42%), out of the 14 selected studies. In addition and among these 14 articles, two studies showed activities in the central nervous system (14.28%), two other studies in metabolism (14.28%) and two in the digestive tract (14.28%). Other important findings, such as the most commonly used route of administration in studies with a-and b-amyrin from P. heptaphyllum and doses used, are described in the Table II .
C H A R A C T E R I S T I C S O F A M Y R I N S
Terpenoids and amyrins
The terpenoids are widely distributed in nature and are found in abundance in higher plants. They represent Figure 2 Flow chart of the process of identification, selection and inclusion of the studies, elaborated from the recommendation PRISMA. the second largest class of secondary metabolites with more active constituents. It is now known that terpenes with a pleasant aroma are extracted from the vegetable essences, while others are the basis of conventional medicaments or the plants containing them, and some are precursors of vitamins and insecticides [9] . They are subdivided into classes and are characterized by molecular composition of C 5 H 8 type of unit called isoprene; therefore, these compounds are also called isoprenoids [12] . During the formation of terpenoids, the isoprene units are connected, and the number of units incorporated into each terpenoid is the basis for the classification of these compounds. Thus, we have the monoterpenes formed by two isoprene units; the sesquiterpenes containing three isoprene units; the diterpenes with four isoprene units; the triterpenes composed of six units; and tetraterpenes carotenoid with eight units [12] .
The pentacyclic triterpenes can be divided into four main groups: oleanane, ursane, lupane and hopane. b- Orofacial pain attenuated at least in part through a peripheral opioid mechanism.
[27]
Anti-inflammatory 10, 30 and 100 o.p. a-and b-amyrin attenuated the L-arginine-induced increases in pancreatic wet weight/body weight ratio, and decreased the serum levels of amylase lipase, TNF-a and IL-6.
[21]
Anti-inflammatory 10, 30 and 100 o.p. a-and b-amyrin suppressed the pancreatic edema, inflammatory cell infiltration, acinar cell necrosis, and expressions of TNF-a and iNOS.
[20]
Anti-inflammatory 10, 25 and 50 i.p. The effect of a-and b-amyrin may be related to a potential involvement of prostaglandins and inhibition of TNF-a.
[24]
Anti-inflammatory 5 and 10 o.p. a-and b-amyrin causes reduction of cell migration and lipid peroxidation, in addition to levels of TNF-a and MPO in gingival periodontitis.
[28]
Anti-inflammatory 50, 100 and 200 o.p. The antipruritus effect caused by AMY may be related to the inhibition of mast cell degranulation caused by compound 48/80.
[29]
Anxiolytic and antidepressant 2.5, 5,10, 25 and 50 i.p. a-and b-amyrin interacts with the GABA-A receptor and also increases noradrenergic activity.
[17] Anticonvulsant 10, 25 and 50 i.p. a-and b-amyrin anticonvulsant activity is related to the GABAergic system and may be linked to the inhibition of the signaling cascade of PKC.
[18]
Gastroprotection 50 and 100 o.p. a-and b-amyrin causes gastroprotection through the activation of primary afferent neurons sensitive to capsaicin.
[30]
Hepatoprotector 50 and 100 i.p. Attenuated the increase in serum ALT and AST activities induced by acetaminophen, increased hepatic glutathione and reduced histopathological changes.
[31]
Antihyperglycemic and hypolipidemic 10, 30 and 100 o.p. a-and b-amyrin significantly decreased glycemic, total cholesterol and serum triglyceride levels in diabetic animals [33] Weight Gain Reducer 10 and 20 o.p. a-and b-amyrin caused a reduction in body weight gain induced by the high-fat diet, and reduced the range of peroxisome proliferator-activated receptors and lipoprotein lipase and blood glucose and insulin levels.
[36]
i.p., intra peritoneal; o.p., oral pathway; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRPV 1 , transient receptor potential vanilloid 1;
TNF-a, tumor necrosis factor alpha; IL-6, interleukin 6; GABA-A, type A gamma-aminobutyric acid receptor; PKC, protein kinase C; MPO, myeloperoxidase. Pharmacological effects of the mixture of alpha and beta amyrin amyrin is an oleanane and a-amyrin is an ursane, and the aglycone of b-type amyrin has two methyls in C-20 [12, 13] . Ursane of a-amyrin type have a methyl and the other C-20 to C-19 with the stereochemistry between D/E rings in the cis form. The triterpene lupeol type differs in the stereochemistry between D/E rings, which is trans and the carbon number of the fifth ring (E), which is formed by five carbon atoms [13] . Amyrins can be found in various plants and plant materials such as leaves, bark, wood, and resins. This material has to be pre-treated prior to isolation of the target compounds. First, the plant material is usually dried, then ground into a powder and sieved. Second, extractions are carried out with dichloromethane, chloroform, n-hexane and methanol. The samples can be subjected to alkaline hydrolysis, derivatization and separation by thin layer chromatography, and the resulting material can be directly subjected to analysis. Gas chromatography and high-performance thin layer chromatography techniques are the most commonly employed methods to quantitate amyrins in plants [1, 2, 13] .
Toxicity
In the current literature, there are few studies and clinical trials using pentacyclic triterpenes that describe the toxicity of these compounds, probably due to its insolubility in water and its low cytotoxic activity in vitro. However, the problems of galenic order can be solved by derivatization, complexation [14, 15] or liposomal formulation [16] . In the literature, there are no reports on the in vivo toxicological potential of AMY from P. heptaphyllum.
Anticonvulsant, anxiolytic and antidepressant effects Triterpenes isolated from species of medicinal plants are in general responsible for, at least, part of their biological activities. The presence of sedative, anxiolytic and antidepressant activities was demonstrated in the mixture of AMY, that possibly involve the GABAergic as well as the noradrenergic systems [17] .
AMY has anticonvulsant activity, showed in experimental models, by the oral pathway (o.p.) and intraperitoneal (i.p.) routes in acute and sub-chronic treatments, where GABAergic mechanisms may be involved, and the participation of the Protein Kinase C (PKC) signaling pathway may also contribute. The doses used were 10, 25 and 50 mg/kg. The changes in the balance between excitatory and inhibitory amino acids may be a factor by which the administration of AMY contributes to neuroprotection [18] .
The anxiolytic and antidepressant effects of AMY were demonstrated by the open-field, elevated-plusmaze, rota rod, forced swimming and pentobarbitalinduced sleeping time tests, in mice. In the open-field test, AMY at the doses of 10, 25 and 50 mg/kg, after intraperitoneal or oral administrations, significantly decreased the number of crossings, grooming, and rearing. All these effects were reversed by the pre-treatment intra peritoneal with flumazenil (2.5 mg/kg, i.p.), similarly to those observed with diazepam used as a positive standard. In the elevated-plus-maze test, AMY increased the time of permanence and the number of entrances in the open arms. On the contrary, the time of permanence and the number of entrances in the closed arms were decreased. All these effects were also completely reversed by flumazenil, an antagonist of benzodiazepine receptors [17] .
In the pentobarbital-induced sleeping time test, AMY at the same doses significantly increased the animals' sleeping time duration. In the rota rod test, AMY did not alter motor coordination and thus, was devoid of effects, as related to controls. Because AMY, at the doses of 10 and 25 mg/kg, showed a sedative effect in the open field test, lower doses (2.5 and 5.0 mg/kg) were used in the forced swimming test, producing a decrease in the immobility time, similarly to that of imipramine, the positive control. The effect of AMY was greater when it was administered 15 min after imipramine (10 mg/kg) [17] . These results support the idea that AMY interacts with the type A gamma-aminobutyric acid (GABA-A) receptor, probably on the receptor subtypes that mediate benzodiazepine effects, to produce sedative and hypnotic activities. It also acts to increase the noradrenergic activity, which is one of the possible pathways for its antidepressant activity.
A N T I -I N F L A M M A T O R Y A N D A N A L G E S I C A C T I V I T Y
Compounds that may be effective in inflammatory diseases are of great interest to the pharmaceutical industry. The natural pentacyclic triterpenoid, ursolic acid, has been known to possess potent anti-inflammatory, antioxidant, and antinociceptive effects in various animal models [19] . In several studies, AMY has also demonstrated a great pharmacological applicability in several diseases [17] [18] [19] [20] [21] that have a common feature in their development: inflammation as one of the main mechanisms involved in their genesis [22, 23] . AMY demonstrated peripheral and central analgesic effects independent of the opioid system and also showed a potent anti-inflammatory activity. The antiinflammatory activity was potentiated by both indomethacin and thalidomide, suggesting a potential involvement of prostaglandins and tumor necrosis factor-alpha (TNF-a) inhibitions [24] .
AMY was evaluated on capsaicin-evoked nociception in mice orally administered. AMY (3 and 100 mg/kg) significantly suppressed the nociceptive behaviors evoked by either subplantar (1.6 microg) or intracolonic (149 microg) application of capsaicin. This work suggests that the AMY has an analgesia-inducing effect, possibly involving transient receptor potential vanilloid 1 (TRPV 1 ) and an opioid mechanism [25] . A similar work was published where it is concluded that the antinociceptive potential of AMY possibly involves the opioid and TRPV 1 receptor mechanisms and further suggests that it could be useful to treat visceral pain of intestinal and pelvic origins [26] .
The antinociceptive effect of AMY was also demonstrated in the formalin-or capsaicin-induced orofacial pain model. The animals were treated with AMY (10, 30 and 100 mg/kg, i.p.) with the treatment causing significantly pain inhibition in both models. However, AMY inhibited only the second phase response, that is, pain of inflammatory origin at a dose of 30 mg/kg. In addition, during the capsaicin-induced pain test, AMY (100 mg/kg) also caused pain inhibition. These results provide evidence demonstrating the applicability of AMY in decreasing orofacial pain, at least in part, through a peripheral opioid mechanism; however, additional studies are required to prove its applicability to decrease pain in orofacial pathologies [27] .
In another study, the aim was to evaluate the antiinflammatory potential of triterpene AMY in rats on acute phase periodontitis. Periodontitis was induced by ligature placement around the maxillary right second molar tooth. Rats were pretreated with AMY (5 and 10 mg/kg, p.o.), two hours before the induction of periodontal inflammation. AMY significantly inhibited the periodontitis-associated increases of TNF-a, and the gingival myeloperoxidase (MPO) and thiobarbituric acid-reactive substances. The AMY effect was more prominent at 5 mg/kg. These results provide evidence that AMY retards acute inflammation in rat model of periodontitis and warrant further study on its efficacy to prevent chronic periodontitis-associated bone loss [28] .
In another study, the AMY was examined scratching behavior induced by dextran T40 and compound 48/ 80 in mice. The animals were pretreated orally with AMY (50, 100 and 200 mg/kg) and higher doses (100 and 200 mg/kg) were able to suppress experimental pruritus. Pruritogenic effect of compound 48/80 is attributed to its histamine releasing activity from mast cells and to the membrane permeability increase and activation of mast cell phospholipase D via heterotrimeric GTP-binding proteins reduction. Therefore, one of the conceivable mechanisms for the antipruritic activity of AMY is the inhibition of degranulation of mast cells [29] .
M E T A B O L I S M A N D D I G E S T O R Y T R A C T
Gastroprotective and hepatoprotective activity A study using AMY evaluated the role of capsaicinsensitive afferent neurons in the gastroprotective effect. The maximal gastroprotection that was observed at the dose of 100 mg/kg of AMY was almost abolished in mice with their sensory afferent neurons chemically ablated by a neurotoxic dose of capsaicin, suggesting that the gastro-protective mechanism of AMY mixture involves, at least in part, the activation of capsaicin-sensitive primary afferent neurons [30] .
The hepatoprotection mechanisms exerted by some triterpenes appear to be multiple. It is known that many hepatotoxic agents require activation of a metabolite via the cytochrome P450 (CYP) system in the liver. The AMY exert their hepatoprotective activity by inhibiting enzymes CYP1A and CYP2A. The protective effect of the first models of hepatotoxicity induced by acetaminophen, bromobenzene, thioacetamide, and CCl 4 furosamida in mice may be attributed in part to the inhibition of CYP in the liver [31] . This study indicates the hepatoprotective potential of AMY against toxic liver injury and suggests the decrease in oxidative stress and toxic metabolite formation as likely mechanisms involved in its hepatoprotection, leading to the conclusion that this study supports the traditional use of P. heptaphyllum resin as a medicinal agent and suggests the feasibility of developing herbal drugs for treatment of liver disorders [30, 31] . Pharmacological effects of the mixture of alpha and beta amyrin Anti-pancreatitis and anti-colitis Acute pancreatitis was induced in five groups of rats by L-arginine (2.5 g/kg, i.p, 1 h apart) and 1 h later they received a single oral dose of AMY (10, 30 and 100 mg/kg). Both AMY and methylprednisolone (positive standard) treatments significantly attenuated the L-arginine-induced increase in pancreatic wet weight/ body weight ratio, and decreased the serum levels of amylase and lipase, and TNF-a and interleukin-6. Also, pancreatic levels of MPO activity, malondialdehyde (MDA), and nitrate/nitrite were significantly lower. Histological findings and TNF-a and nitric oxide synthase induced (iNOS) immunostaining further confirmed the amelioration of pancreatic injury by AMY [21] . In another study, AMY and thalidomide significantly attenuated the cerulein-induced increase in TNF-a, IL-6, lipase, amylase, MPO and MDA. Moreover, AMY greatly suppressed the pancreatic edema, inflammatory cell infiltration, acinar cell necrosis, and expressions of TNF-a and iNOS [20] .
Antihyperglycemic and hypolipidemic effects
Pentacyclic triterpenes in general exert beneficial effects in metabolic disorders [32] . One study investigated the effects of AMY, from the resin of P. heptaphyllum, on blood sugar level and lipid profile in normal and streptozotocin (STZ)-induced diabetic mice, and in mice fed on a high-fat diet. The results showed that mice treated orally with AMY (10, 30 and 100 mg/kg) or glibenclamide (10 mg/kg), once a day for 5 days, significantly reduced STZ-induced increases in blood glucose (BG), total cholesterol (TC) and serum triglycerides (TGs). Also, AMY effectively reduced the elevated plasma glucose levels during the oral glucose tolerance test. Moreover, the plasma insulin level and histopathological analysis of pancreas revealed the beneficial effect of AMY in the preservation of beta cell integrity. The hypocholesterolemic effect of AMY appeared more prominent at 100 mg/kg with significant decreases in very low-density lipoprotein and low-density lipoprotein cholesterol and an elevation of high density lipoprotein cholesterol [33] .
Obesity treatment
Currently, researchers are looking for new compounds for the treatment of obesity. Pentacyclic triterpenes have been described in the literature as anti-inflammatory substances and are promising as a possible therapeutic option, considering obesity is a disease that has in its pathophysiology the inflammation as an aggravating factor for the development of complications [34, 35] .
In this context, AMY presents itself as one of these new compounds eligible for obesity therapy, considering it has been shown in the literature that AMY has antihyperglycemic and hypolipidemic effects [33] . A recent study has demonstrated the antiobesity potential of AMY in a model of obesity induced by a high-fat diet in mice. The results showed that AMY treatment (doses of 10 or 20 mg/kg) or sibutramine (10 mg/kg) for 15 weeks resulted in a decrease in body weight, visceral fat content, adipocyte surface area, number of peroxisome proliferator-activated receptors, lipase and glucose levels and insulin in the blood. In addition, AMY also decreases TNF-a and monocyte chemoattractant protein-1 (MCP-1) in serum and has been shown to modulate leptin and ghrelin levels when compared to the control group that only received the high-fat diet. These results demonstrate the potential of AMY to be a new therapeutic option for the reduction of obesity [36] .
F I N A L C O N S I D E R A T I O N S
Regarding the variability found in the scientific studies included in this review, most studies indicate positive effects of AMY, mainly on the modulation of the inflammatory response in acute lesions associated or not with other treatments. Nonetheless, the lack of reports on toxicity of AMY obtained from P. heptaphyllum should be highlighted as it is necessary to know the safety of this substance to allow its use in clinical trials with humans.
In the course of this study, the reader should be able to perceive that different methodologies can generate different variables and therefore contradictory results. However, although the studies show uncertainties, it is possible to emphasize that there is good evidence to support AMY recommendation with the purpose of reducing the inflammatory reaction that occurs in the majority of the cases of diseases that have in their etiology the trigger inflammation.
In conclusion, the present work gathered important information about AMY obtained from P. heptaphyllum, which has been shown in several studies as a promising and viable medicinal agent for the development of drugs based on this compound, considering it has a high potential as treatment for several diseases of inflammatory origin and that there is a need for toxicity tests to be carried out in order to advance studies with this substance. 
